miR‑155 promotes proliferation and epithelial‑mesenchymal transition of MCF‑7 cells

Liu, Xiaoyan; Li, Yongjun; Li, Zhuo; Hou, Tian Tian

doi:10.3892/etm.2021.9650

Cited by 11 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High expression of this miRNA was associated with lymph node metastasis in PDAC patients [94,95]. The mi-croRNA miR-155 was found to induce epithelial-mesenchymal transitions (EMT) in breast, liver, and kidney cancer [96][97][98][99]. MiR-155 promotes (EMT), as well as regulates cancer cell invasion and migration, by modulating the STAT3 signaling pathway in pancreatic cancer cells [64].…”

Section: Discussionmentioning

confidence: 99%

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma

Popov,

Hrudka,

Szabó

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC) of the pancreas represents a rare subtype of pancreatic ductal adenocarcinoma (PDAC). Despite a distinct morphology and specific clinical behavior, UCOGCs exhibit unexpected similarities in regard to DNA mutational profiles with conventional PDAC. Treating pancreatic ductal adenocarcinoma is particularly challenging, with limited prospects for cure. As with many other malignant neoplasms, the exploration of microRNAs (miRNAs, miRs) in regulating the biological characteristics of pancreatic cancer is undergoing extensive investigation to enhance tumor diagnostics and unveil the therapeutic possibilities. Herein, we evaluated the expression of miR-21, -96, -148a, -155, -196a, -210, and -217 in UCOGCs and poorly differentiated (grade 3, G3) PDACs. The expression of miR-21, miR-155, and miR-210 in both UCOGCs and G3 PDACs was significantly upregulated compared to the levels in normal tissue, while the levels of miR-148a and miR-217 were downregulated. We did not find any significant differences between cancerous and normal tissues for the expression of miR-96 and miR-196a in G3 PDACs, whereas miR-196a was slightly, but significantly, downregulated in UCOGCs. On the other hand, we have not observed significant differences in the expression of the majority of miRNAs between UCOGC and G3 PDAC, with the exception of miR-155. UCOGC samples demonstrated lower mean levels of miR-155 in comparison with those in G3 PDACs.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma

Popov,

Hrudka,

Szabó

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Remarkably, with the exception of the uncharacterized miR-3965, all of the miRs that were significantly upregulated at 0.5% O2, concomitant with observed morphological changes, are known to be positively correlated or directly involved in EMT (Fig. 2D) (26)(27)(28)(29)(30)(31)(32)(33)(34)(35). Most notably, miR-221 and miRs-222 are directly involved in EMT (26,27,(36)(37)(38).…”

Section: Lthy Adaptation Upregulates Emt-promoting Mirsmentioning

confidence: 96%

Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms Tumor 1 (WT1) isoform

Quenneville,

Feghaly,

Tual

et al. 2023

Preprint

View full text Add to dashboard Cite

The majority of cancer deaths are caused by solid tumors, where the four most prevalent cancers (breast, lung, colorectal and prostate) account for more than 60% of all cases (1). Tumor cell heterogeneity driven by variable cancer microenvironments, such as hypoxia, is a key determinant of therapeutic outcome. We developed a novel culture protocol, termed the Long-Term Hypoxia (LTHY) time course, to recapitulate the gradual development of severe hypoxia seenin vivo, to mimic conditions observed in primary tumors. Cells subjected to LTHY underwent a non-canonical epithelial to mesenchymal transition (EMT) based on miRNA and mRNA signatures as well as displayed EMT-like morphological changes. Concomitant to this, we report production of a novel truncated isoform of WT1 transcription factor (tWt1), a non-canonical EMT driver, with expression driven by a yet undescribed intronic promoter through hypoxia-responsive elements (HREs). We further demonstrated that tWt1 initiates translation from an intron-derived start codon, retains proper subcellular localization, DNA binding, and its human ortholog negatively predicts long-term patient survival. Our study demonstrates the importance of culture conditions that better mimic those observed in cancers, especially with regards to hypoxia, and identifies a novel isoform of WT1 which correlates with poor long-term survival in ovarian cancer.

show abstract

Role of miRNAs in breast cancer development and progression: Current research

Kumar,

Ranga

2024

BioFactors

View full text Add to dashboard Cite

Breast cancer, a complex and heterogeneous ailment impacting numerous women worldwide, persists as a prominent cause of cancer‐related fatalities. MicroRNAs (miRNAs), small non‐coding RNAs, have garnered significant attention for their involvement in breast cancer's progression. These molecules post‐transcriptionally regulate gene expression, influencing crucial cellular processes including proliferation, differentiation, and apoptosis. This review provides an overview of the current research on the role of miRNAs in breast cancer. It discusses the role of miRNAs in breast cancer, including the different subtypes of breast cancer, their molecular characteristics, and the mechanisms by which miRNAs regulate gene expression in breast cancer cells. Additionally, the review highlights recent studies identifying specific miRNAs that are dysregulated in breast cancer and their potential use as diagnostic and prognostic biomarkers. Furthermore, the review explores the therapeutic potential of miRNAs in breast cancer treatment. Preclinical studies have shown the effectiveness of miRNA‐based therapies, such as antagomir and miRNA mimic therapies, in inhibiting tumor growth and metastasis. Emerging areas, including the application of artificial intelligence (AI) to advance miRNA research and the “One Health” approach that integrates human and animal cancer insights, are also discussed. However, challenges remain before these therapies can be fully translated into clinical practice. In conclusion, this review emphasizes the significance of miRNAs in breast cancer research and their potential as innovative diagnostic and therapeutic tools. A deeper understanding of miRNA dysregulation in breast cancer is essential for their successful application in clinical settings. With continued research, miRNA‐based approaches hold promise for improving patient outcomes in this devastating disease.

show abstract

miR‑155 promotes proliferation and epithelial‑mesenchymal transition of MCF‑7 cells

Cited by 11 publications

References 29 publications

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma

Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms Tumor 1 (WT1) isoform

Role of miRNAs in breast cancer development and progression: Current research

Contact Info

Product

Resources

About